Delcath Systems Inc
NASDAQ:DCTH
| Market Cap (Intraday) | 81.53M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $11.28 |
| 50-Day MA | $11.56 |
| 200-Day MA | $14.26 |
Delcath Systems Inc Stock, NASDAQ:DCTH
1633 Broadway, Suite 22 C, New York, New York 10019
United States of America
Phone: +1.212.489.2100
Number of Employees: 36
Description
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.